An author name was incorrectly spelled as “Maria De Filippo”. The correct spelling is “Maria Rosaria De Filippo”.
In the published article, there was also an error in affiliation 1. Instead of “Department of BioMedical Research, University of Bern, Bern, Switzerland”, it should be “Department for BioMedical Research, Urology Research Laboratory, University of Bern, Bern, Switzerland”.
There was also an error in the text. The concentration and administration schedule of Rapalink-1 reported for the in vivo experiment was not correct. The error appeared both in the “Materials and Methods” and in the “Results” sections, where it is incorrectly reported as “1.5 mg/g [ … ] every 5 days” and “1.5 mg/g/6 days”, respectively. Figure 5C in the original article reported the correct administration schedule.
A correction has been made to the “Materials and Methods” section, “Animals Maintenance and in vivo Experiment” sub-section:
“Group 1 received 3.5 μl/g of vehicle (20% DMSO, 40% PEG-300 and 40% PBS) i.p. once a week while group 2 received Rapalink-1 (1.5 mg/Kg) resuspended in vehicle, i.p. every 5-7 days.”
A correction of the same error has been made to the “Results” section, “Treatment of LAPC9 in vivo With Rapalink-1 Delays Tumor Growth” sub-section, paragraph 2:
“We then assessed the effect of Rapalink-1 (1.5 mg/Kg/5-7 days) in vivo on LAPC9 PDX model, comparing the treatment to vehicle only, a schematic of treatment schedule is reported (Figure 5C).”
The authors apologize for these errors and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.
Summary
Keywords
bone metastasis, PDX, mTOR, disulfiram, prostate cancer, ALDH
Citation
La Manna F, De Menna M, Patel N, Karkampouna S, De Filippo MR, Klima I, Kloen P, Beimers L, Thalmann GN, Pelger RCM, Jacinto E and Kruithof-de Julio M (2021) Corrigendum: Dual-mTOR Inhibitor Rapalink-1 Reduces Prostate Cancer Patient-Derived Xenograft Growth and Alters Tumor Heterogeneity. Front. Oncol. 11:650623. doi: 10.3389/fonc.2021.650623
Received
07 January 2021
Accepted
15 January 2021
Published
03 February 2021
Volume
11 - 2021
Edited and reviewed by
Maria Teresa Valenti, University of Verona, Italy
Updates
Copyright
© 2021 La Manna, De Menna, Patel, Karkampouna, De Filippo, Klima, Kloen, Beimers, Thalmann, Pelger, Jacinto and Kruithof-de Julio.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Marianna Kruithof-de Julio, marianna.kruithofdejulio@dbmr.unibe.ch
This article was submitted to Molecular and Cellular Oncology, a section of the journal Frontiers in Oncology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.